An interleukin (IL-23) inhibitor biologic
Risankizumab
An injected biologic that blocks the IL-23 immune signal, used for psoriasis, psoriatic arthritis and Crohn's disease.
What is Risankizumab?
Risankizumab is a biologic medicine that calms an overactive immune system by blocking interleukin-23 (IL-23), a messenger protein that drives inflammation. It is used for moderate to severe plaque psoriasis, psoriatic arthritis and Crohn's disease. It is given by injection under the skin, which many people learn to do themselves, with doses spaced weeks apart once established. Because it dampens part of the immune system, infection is the main caution, so you are usually screened for tuberculosis and hepatitis first and should avoid live vaccines during treatment.
Education and reference only. This is a plain-language guide to Risankizumab — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Risankizumab is a biologic medicine, made from living cells, that targets a specific immune signal called interleukin-23. IL-23 is one of the key messengers driving the inflammation behind psoriasis and some other immune conditions. Risankizumab is used for moderate to severe plaque psoriasis, psoriatic arthritis and the inflammatory bowel condition Crohn's disease, usually when other treatments have not worked well enough. It is given by injection under the skin, and many people are trained to give it themselves at home; for Crohn's disease the first doses may be given as a drip into a vein in hospital.
How it works
In psoriasis and related conditions, the immune system over-produces signals that fuel inflammation. Risankizumab attaches to interleukin-23, an early signal that drives this process, so the immune system stops being pushed to produce the thickened, scaly skin, joint swelling or bowel inflammation. Because it blocks one specific upstream signal rather than suppressing the whole immune system, it is a focused treatment, although it still leaves you somewhat more prone to infection.
Company & origin
Originated / developed by: AbbVie.
A biologic medicine developed to treat moderate to severe plaque psoriasis, psoriatic arthritis and Crohn's disease by blocking the immune signal IL-23.
Practical use
How to take Risankizumab
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given by injection under the skin, often with a pre-filled pen that many people learn to use themselves at home.
- For Crohn's disease, the first doses may be given as a drip into a vein in hospital before switching to under-the-skin injections.
- Before starting, expect screening for tuberculosis and hepatitis so a hidden infection does not flare during treatment.
- Avoid live vaccines while being treated, and aim to be up to date with recommended non-live vaccinations beforehand.
- Tell your team promptly about any fever, persistent cough or infection that will not settle, and keep your review appointments.
Weighing it up
Advantages & disadvantages of Risankizumab
Advantages
- Often very effective at clearing moderate to severe plaque psoriasis and easing psoriatic arthritis and Crohn's disease.
- Targets one specific upstream immune signal, so it is more focused than older, broad immunosuppressants.
- Generally well tolerated, can be self-injected at home after training, with doses spaced weeks apart.
Disadvantages
- It dampens part of the immune system, so it can make infections more likely and may let a hidden tuberculosis or hepatitis infection flare.
- Live vaccines must be avoided during treatment.
- It is a biologic given by injection and needs screening before starting and ongoing monitoring.
Practical use
Good to know
The main point is that risankizumab quietens part of the immune system, so infection is the key caution, even though it is more focused than older broad immunosuppressants. Before you start, you are usually screened for tuberculosis and hepatitis so a hidden infection does not flare, and you should avoid live vaccines while being treated; it helps to be up to date with recommended non-live vaccinations beforehand. Tell your team promptly about any fever, persistent cough or infection that will not settle. IL-23 blockers like this are generally well tolerated. After training, most people give the injections themselves at home, with doses spaced weeks apart once established; for Crohn's disease the first doses may be given as a drip in hospital.
Who should not take it / use with caution
- People with a serious active infection should not start it until the infection is treated.
- It is used only after assessment in those with untreated tuberculosis or active hepatitis.
- Live vaccines should be avoided during treatment, so this needs planning around any immunisations.
Monitoring
- Screening for tuberculosis and hepatitis before starting, and watching for infection throughout treatment.
- Reviewing how well the skin, joints or bowel symptoms are responding so treatment can be adjusted.
- Checking vaccination status and planning any immunisations around the treatment.
Side effects
- More frequent infections, such as colds and chest or sinus infections, are the most important effect to watch for.
- Headache, tiredness, and redness or soreness where the injection is given, which are usually mild.
- Rarely, more serious infections or allergic reactions, which need urgent medical attention.
Key interactions
- Combining it with other medicines that suppress the immune system adds to the infection risk and is done only with specialist advice.
- Live vaccines should not be given during treatment.
- Tell your team about all your medicines and any long-term conditions, as some affect how it is used.
Available as: Injection under the skin (including pre-filled pens for self-injection after training); an initial dose into a vein for Crohn's disease.
Answers
Risankizumab: frequently asked questions
How does risankizumab work?
It blocks interleukin-23 (IL-23), an early immune signal that drives the inflammation behind psoriasis and related conditions, calming the overactivity that causes the symptoms.
How is it given?
It is given by injection under the skin and many people self-inject at home after training; for Crohn's disease the first doses may be given as a drip into a vein in hospital.
Why do I need tests before starting?
You are usually screened for tuberculosis and hepatitis first, because calming part of the immune system can let a hidden infection flare.
Can I have vaccinations during treatment?
You should avoid live vaccines while being treated; it is best to be up to date with recommended non-live vaccines beforehand, and your team can advise.
How often will I need it?
Once treatment is established, injections are usually spaced weeks apart, which many people find convenient, and most can self-inject at home.
The wider class
About Interleukin (IL-23) inhibitor biologic
Risankizumab belongs to the interleukin (il-23) inhibitor biologic class. For how the class as a whole works, its shared safety principles and monitoring, see the full guide.
Browse by body system
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.